Development of a Biomimetic Vitreous Substitute

仿生玻璃体替代品的开发

• 批准号: 8826126
• 负责人: Nathan RAVI
• 金额: $ 36.65万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-04-01 至 2017-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8826126
• 关键词: 3-Dimensional; Alkanes; Architecture; Biodegradation; Biological Assay; Biomimetics; Blindness; Cataract; Cell Line; Circular Dichroism; Clinical; Clinical Trials; Collagen; Complex; Cornea; Data; Development; Disease; Disulfides; Drug Delivery Systems; Drug Formulations; Engineering; Evaluation; Excision; Exposure to; Eye; Fibroblasts; Fluorocarbons; Fourier Transform; Future; Gases; Gel; Glaucoma; Goals; Growth; Health; Hyaluronic Acid; Hydrogels; Hydrophobicity; Implant; In Vitro; Incidence; Inflammation; Injection of therapeutic agent; Intervention; Knowledge; Lead; Light-Scattering Spectroscopy; Literature; Mechanics; Methods; Mission; Modeling; Molecular; Molecular Profiling; Molecular Weight; Nature; Nuclear; Nuclear Magnetic Resonance; Operative Surgical Procedures; Ophthalmologic Surgical Procedures; Optics; Oryctolagus cuniculus; Osmotic Pressure; Outcome; Oxygen; Patients; Pharmacotherapy; Physiological; Physiology; Play; Polymers; Polysaccharides; Prevention; Property; Public Health; Refractive Errors; Research; Resistance; Retina; Retinal; Retinal Detachment; Rheology; Role; Side; Silicone Oils; Sodium; Sodium Chloride; Solutions; Structure; Sulfhydryl Compounds; Surgical complication; System; Techniques; Testing; Translating; United States National Institutes of Health; Vision; Vitrectomy; Water; analog; anterior chamber; aqueous; base; biomaterial compatibility; condensed matter physics; copolymer; crosslink; design; expectation; flexibility; gellan; improved; in vivo; innovation; light scattering; methacrylamide; novel strategies; organizational structure; outcome forecast; pressure; repaired; success; tissue culture; tool

DESCRIPTION (provided by applicant): Surgical removal of the vitreous and its replacement with substitutes has become the most common posterior segment eye surgery. Present substitutes, while functional, are temporary and are either absorbed (gases) or require secondary surgery for removal (silicone oils). Surgical complications include development of nuclear cataract, glaucoma, corneal decompensation, and retinal re-detachments. Our long-term objective is to deepen our understanding of the macromolecular organization of the vitreous components and then to use this information to develop more physiological vitreous substitutes that can exert an osmotic pressure to tamponade the retina. Our central hypothesis is that we can accomplish this by using water-soluble thiolated synthetic analogues of the collagen and hyaluronic acid, the two primary components of the vitreous. In our specific aims we will substitute collagen with deacylated gellan while hyaluronic acid will be substituted by a methacrylamide/sodium methacryate copolymer. Statistically designed polymers and their hydrogels will be characterized using nuclear magnetic resonance, Fourier transform infrared, raman, circular dichroism, and light- scattering spectroscopies, and rheology. Computational and macromolecular modeling techniques will be employed to study the relationship between the structure and mechanical properties of the natural vitreous. It is our expectation that the techniques will enable us to develop a 3-D molecular profile of the vitreous in vivo by using light scattering techniques. Vitreous substitutes will be further tested by using light scattering, tisse culture and one-month in vivo rabbit studies followed by examination of the implant and histological evaluation of the retina. Our goal is to generate optimal biomimetic formulations of vitreous substitutes to be potentially translated into clinical interventions. This contribution wll be significant because these physiological gel substitutes could lessen patient burden by eliminating the need for removal of the substitute by secondary surgery, eliminating refractive error, possibly lowering the incidence of glaucoma and cataract postvitrectomy, and reducing redetachment of the retina. They could also be used to study the molecular mechanism of vitreous liquefaction and for intravitreal drug delivery therapies. The proposed research is innovative because it focuses on understanding and mimicking the natural vitreous and utilizing recent advances in soft condensed matter physics. Our two-component system representing rigid collagen and flexible hyaluronic acid will be endowed with sticky thiol groups. After injection of material as an aqueous solution, the rigid component will instantaneously form a physical gel imbedding the flexible copolymer. Upon subsequent exposure to oxygen, the thiol groups in the two components will form disulfide cross-links, resulting in a permanent hydrogel capable of providing osmotic pressure to tamponade the retina.

描述（由申请人提供）：手术切除玻璃体并用替代物置换已成为最常见的眼后段手术。 目前的替代品，虽然功能，是暂时的，要么吸收（气体）或需要二次手术去除（硅油）。 手术并发症包括核性白内障、青光眼、角膜失代偿和视网膜再脱离。 我们的长期目标是加深我们对玻璃体成分的大分子组织的理解，然后利用这些信息开发更多的生理玻璃体替代品，可以施加渗透压来填塞视网膜。 我们的中心假设是，我们可以通过使用胶原蛋白和透明质酸（玻璃体的两种主要成分）的水溶性硫醇化合成类似物来实现这一点。 在我们的具体目标中，我们将用脱酰结冷胶代替胶原蛋白，而透明质酸将用甲基丙烯酰胺/甲基丙烯酸钠共聚物代替。 统计设计的聚合物和它们的水凝胶将使用核磁共振、傅里叶变换红外、拉曼、圆二色性和光散射光谱以及流变学来表征。 利用计算和高分子模拟技术研究天然玻璃体的结构和力学性能之间的关系。 我们期望该技术能使我们利用光在活体内建立玻璃体的三维分子轮廓 散射技术 将通过使用光散射、组织培养和一个月的兔体内研究进一步测试玻璃体替代物，然后检查植入物和视网膜的组织学评价。 我们的目标是生成玻璃体替代物的最佳仿生制剂，以潜在地转化为临床干预。 这一贡献将是重要的，因为这些生理凝胶替代物可以通过消除通过二次手术去除替代物的需要来减轻患者负担，消除屈光不正，可能降低玻璃体切除术后青光眼和白内障的发病率，并减少视网膜再脱离。 它们也可用于研究玻璃体液化的分子机制和用于玻璃体内药物递送治疗。 这项研究具有创新性，因为它专注于理解和模仿天然玻璃体，并利用软凝聚态物理学的最新进展。 我们的代表刚性胶原蛋白和柔性透明质酸的双组分系统将被赋予粘性硫醇基团。 在注入作为水溶液的材料之后，刚性组分将立即形成嵌入柔性共聚物的物理凝胶。 在随后暴露于氧气时，两种组分中的硫醇基团将形成二硫键交联，从而产生能够提供渗透压以填塞视网膜的永久性水凝胶。